Umeclidinium
Medication
long-acting antimuscarinic bronchodilator
respiratory
Not medical advice. Check with your doctor or pharmacist before you start, stop or change the timing of anything you take.
How to use
What it’s for
SG label: maintenance copd treatment, to relieve symptoms
When to take
SG label: one inhalation once daily, SAMe time each day
Take with
Inhaled · a short-acting reliever covers sudden symptoms
Pros & cons
Pros
- SG label: one inhalation once daily, nothing to swallow
- SG label: no dose change for age or kidney problems
- US label: no dose change in moderate liver problems
Cons
- US label: not for relief of acute symptoms
- US label: can worsen narrow-angle glaucoma
- US label: can worsen urinary retention
Sources
- HSA — Listing of Registered Therapeutic Products (data.gov.sg open dataset, 5,511 rows, cached in full and filtered locally) · read 2026-08-27
what it says
“All 4 umeclidinium rows read 'Prescription Only' — INCRUSE ELLIPTA 62.5 MCG/DOSE (umeclidinium alone, R03BB07) · ANORO ELLIPTA 62.5/25 (with vilanterol) · TRELEGY ELLIPTA 100/62.5/25 and 200/62.5/25 (with fluticasone furoate and vilanterol)”
- National Drug Formulary (SG, MOH) — INCRUSE ELLIPTA INHALATION POWDER 62.5 MCG/DOSE [SIN14853P], indications, dosing and contraindications, last updated 28 Jul 2026 · read 2026-08-27
what it says
“indicated for maintenance bronchodilator treatment to relieve symptoms associated with chronic obstructive pulmonary disease (COPD) … The recommended dose is one inhalation of INCRUSE ELLIPTA once daily … contraindicated in patients with severe milk-protein allergy”
- National Drug Formulary (SG, MOH) — TRELEGY ELLIPTA INHALATION POWDER 100/62.5/25 MCG [SIN15806P], Dosage and Administration · read 2026-08-27
what it says
“The maximum recommended dosage is 1 inhalation of Trelegy Ellipta 200/62.5/25 mcg once daily … Do not use Trelegy Ellipta more than 1 time every 24 hours.”
- US FDA label — INCRUSE ELLIPTA (umeclidinium, GSK), section 1 Indications and Usage, via openFDA (effective 13 Dec 2023) · read 2026-08-27
what it says
“INCRUSE ELLIPTA is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).”
- US FDA label — INCRUSE ELLIPTA, section 2 Dosage and Administration, via openFDA · read 2026-08-27
what it says
“INCRUSE ELLIPTA should be used at the same time every day. Do not use INCRUSE ELLIPTA more than 1 time every 24 hours … No dosage adjustment is required for geriatric patients, patients with renal impairment”
- US FDA label — INCRUSE ELLIPTA, section 5 Warnings and Precautions, via openFDA · read 2026-08-27
what it says
“Do not initiate in acutely deteriorating COPD. Do not use to treat acute symptoms … Acute symptoms should be treated with an inhaled, short-acting beta2-agonist … Worsening of narrow-angle glaucoma may occur … Worsening of urinary retention may occur”
- US FDA label — INCRUSE ELLIPTA, section 7 Drug Interactions, via openFDA · read 2026-08-27
what it says
“Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs.”
- US FDA label — ANORO ELLIPTA (umeclidinium and vilanterol, GSK), section 2 Dosage and Administration, via openFDA (effective 2 Jun 2023) · read 2026-08-27
what it says
“The recommended dosage of ANORO ELLIPTA for maintenance treatment of COPD is 62.5 mcg umeclidinium and 25 mcg vilanterol … once daily by oral inhalation … Do not use ANORO ELLIPTA more than 1 time every 24 hours.”
Updated 2026-08-29. Every line above traces to a numbered source. Kozen-X is not a medical device and does not give medical advice. It lists what published sources have written down — nothing more. A pair not listed is unrecorded, not cleared. Before you start, stop or re-time anything, talk to your doctor or pharmacist.